Return to Trial Database

HCRN-BRE17-141

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER2-Positive Breast Cancers

Status

Currently Enrolling

Cancer Type(s)

Study Contact

Trial Locations

All sites in which the trial HCRN-BRE17-141 being conducted in.

Penn State Cancer Institute

University of Illinois Cancer Center

University of Rochester Medical Center - Wilmot Cancer Institute

University of Wisconsin Carbone Cancer Center